Skip to content

Early diagnosis of Alzheimer's disease based on noninvasive quantitative detection of ß-amyloidal plaque in fundus

Early diagnosis of Alzheimer's disease based on noninvasive quantitative detection of ß-amyloidal plaque in fundus

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035243
Enrollment
Unknown
Registered
2020-08-05
Start date
2020-08-20
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Gold Standard:Clinical symptoms, neuropsychological scale, imaging indicators.
Index test:Fundus&#32
image,&#32
photographic&#32
image&#32
and&#32

Sponsors

Ningbo Kangning Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male or postmenopausal women, aged 60-75 years; 2. Those who meet the criteria of ICD-10 for the clinical diagnosis of Alzheimer's disease; 3. Subjects with MMSE score lower than 25; 4. Have the ability to complete the cognitive ability test and the test objects specified in the program; 5. Hachinski ischemic scale score = 4, excluding vascular factors; 6. Hamilton Depression Scale (HAMD) 24 item version total score = 8, excluding depression factors.

Exclusion criteria

Exclusion criteria: 1. Patients with severe physical diseases, such as severe heart disease, malignant tumor, etc; 2. Patients with severe mental symptoms or mental illness, such as schizophrenia; 3. Patients with alcohol and drug abuse; 4. Patients with severe depression and serious suicide risk; Five Patients with dementia caused by other causes: vascular dementia, central nervous system infection (such as AIDS, syphilis, etc.), Lewy body dementia, traumatic dementia, other physical and chemical factors (such as drug poisoning), intracranial space occupying lesions (such as subdural hematoma, brain tumors), endocrine system lesions (such as thyroid disease, parathyroid disease), vitamins or other Dementia of any cause. 6. History or screening of patients with brain MRI showing the following abnormalities: cerebral hemorrhage, brain trauma, aneurysm, arteriovenous malformation, subdural hematoma, intracranial space occupying, etc; 7. Patients who have undergone ophthalmic surgery recently; 8. Patients with other conditions considered unsuitable for the study; 9. Those who do not sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Fudus Aß content;

Secondary

MeasureTime frame
Thickness of retina;

Countries

China

Contacts

Public ContactMei Xi

Ningbo Kangning Hospital

meixi18401856@163.com+86 15867562569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026